91 pending office actions • 56 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18844546 | Modulation of Protein Levels | Carlsberg A/S | KEOGH, MATTHEW R | 1663 | Non-Final OA | Sep 06, 2024 |
| 18649569 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. | SAMALA, JAGADISHWAR RAO | 1618 | Non-Final OA | Apr 29, 2024 |
| 18640699 | Parabacteroides Goldsteinii to Treat or Prevent Inflammatory and AutoImmune Diseases | Joslin Diabetes Center | DEVI, SARVAMANGALA | 1645 | Non-Final OA | Apr 19, 2024 |
| 18690358 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | Haihe Biopharma Co., Ltd. | TOWNSLEY, SARA ELIZABETH | 1629 | Non-Final OA | Mar 08, 2024 |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | The Scripps Research Institute | JONES, CHRISTINE MICHELLE | 1682 | Non-Final OA | Jan 26, 2024 |
| 18415032 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | Intellia Therapeutics, Inc. | REGA, KYLE THOMAS | 1636 | Final Rejection | Jan 17, 2024 |
| 18543912 | PSGL-1 Antagonists and Uses Thereof | Five Prime Therapeutics, Inc. | LANDSMAN, ROBERT S | 1647 | Non-Final OA | Dec 18, 2023 |
| 18560763 | METHODS OF TREATING DEPRESSION AND ANXIETY | Woolsey Pharmaceuticals, Inc. | HABTE, KAHSAY | 1624 | Non-Final OA | Nov 14, 2023 |
| 18560760 | METHODS OF TREATING DEPRESSION AND ANXIETY | Woolsey Pharmaceuticals, Inc. | LEE, WILLIAM Y | 1623 | Non-Final OA | Nov 14, 2023 |
| 18557661 | Topical Compositions Comprising (Glyco)Sphingolipids and/or (Glyco)Ceramides | Carbocode S.A. | KRISHNAN, GANAPATHY | 1693 | Non-Final OA | Oct 27, 2023 |
| 18557852 | PKC-Theta Modulators | Celgene Corporation | RAO, PADMAJA S | 1627 | Final Rejection | Oct 27, 2023 |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | Aardvark Therapeutics, Inc. | HIBBERT, CATHERINE S | 1658 | Non-Final OA | Oct 25, 2023 |
| 18555065 | APPARATUS FOR AND METHOD OF OBTAINING A BIOLOGICAL SAMPLE FROM A SURFACE | Cerdak (Pty )Ltd | ABOUELELA, MAY A | 3791 | Non-Final OA | Oct 12, 2023 |
| 18478542 | Methods of Treating Cancer with Anti-TIGIT Antibodies | Seagen Inc. | MACFARLANE, STACEY NEE | 1675 | Non-Final OA | Sep 29, 2023 |
| 18374902 | PREPARATION AND PURIFICATION PROCESS OF MONOMETHYL AURISTAIN E COMPOUND | Remegen Co., Ltd. | HA, JULIE | 1654 | Non-Final OA | Sep 29, 2023 |
| 18375175 | PREPARATION AND PURIFICATION METHOD OF ANTIBODY DRUG CONJUGATE INTERMEDIATE | Remegen Co., Ltd. | PUTTLITZ, KARL J | 1646 | Non-Final OA | Sep 29, 2023 |
| 18282402 | TMEM173 saRNA Compositions and Methods of Use | Mina Therapeutics Limited | HUDSON, AMY ROSE | 1636 | Non-Final OA | Sep 15, 2023 |
| 18466575 | MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS | Vertex Pharmaceuticals Incorporated | POPA, ILEANA | 1633 | Non-Final OA | Sep 13, 2023 |
| 18549237 | METHODS OF TREATING 4-REPEAT TAUOPATHIES | Woolsey Pharmaceuticals, Inc. | MOORE, SUSANNA | 1624 | Non-Final OA | Sep 06, 2023 |
| 18279612 | Compositions and Methods For Reducing Immune Intolerance | Lapix Therapeutics, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Aug 31, 2023 |
| 18456288 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SluCas9 | Vertex Pharmaceuticals Incorporated | ALLEN, SARAH ELIZABETH | 1637 | Non-Final OA | Aug 25, 2023 |
| 18450498 | Product for the Storage of Freeze-Dried Lactic Acid Bacteria Mixed with Oral Rehydration Solution | BIOGAIA AB | DUBOIS, PHILIP A | 1791 | Non-Final OA | Aug 16, 2023 |
| 18546155 | Methods for Treating Multiple Myeloma | Celgene Corporation | BENAVIDES, JENNIFER ANN | 1675 | Non-Final OA | Aug 11, 2023 |
| 18447623 | Use of Anti-Il-6 Antibody, e.g., Clazakizumab for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing Antibody Mediated Rejection (ABMR) | Cedars-Sinai Medical Center | GAO, ASHLEY HARTMAN | 1678 | Non-Final OA | Aug 10, 2023 |
| 18276309 | Compounds and Their Use as PDE4 Activators | Mironid Limited | SHTERENGARTS, SAMANTHA L | 1623 | Non-Final OA | Aug 08, 2023 |
| 18366064 | Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy | Intellia Therapeutics, Inc. | STAVROU, CONSTANTINA E | 1632 | Non-Final OA | Aug 07, 2023 |
| 18366117 | T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy | Intellia Therapeutics, Inc. | POPA, ILEANA | 1633 | Non-Final OA | Aug 07, 2023 |
| 18264475 | Formulations of DR5 Binding Polypeptides | Inhibrx Biosciences, Inc. | CESARE, JOSEPH DAVID | 1675 | Non-Final OA | Aug 07, 2023 |
| 18274180 | DENATONIUM SALT FOR USE IN PREVENTING, PREVENTING PROGRESSION AND TREATING FATTY LIVER DISEASES | Aardvark Therapeutics Inc. | HAVLIN, ROBERT H | 1626 | Final Rejection | Jul 25, 2023 |
| 18357007 | Antibodies Binding to Human PAD4 and Uses Thereof | Bristol-Myers Squibb Company | GURLEY, JAMI MICHELLE | 1647 | Non-Final OA | Jul 21, 2023 |
| 18223768 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | Celgene Corporation | VALLE, ERNESTO | 1623 | Non-Final OA | Jul 19, 2023 |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | Intellia Therapeutics, Inc. | SMALL, KATHERINE R | 1633 | Non-Final OA | Jun 22, 2023 |
| 18334680 | Glycan-Interacting Compounds and Methods of Use | Seagen Inc. | BORGEEST, CHRISTINA M | 1675 | Non-Final OA | Jun 14, 2023 |
| 18267226 | Heterocyclic Compounds and Their Use for Parasitic Diseases | Celgene Corporation | MAHLUM, JONATHAN DAVIS | 1625 | Non-Final OA | Jun 14, 2023 |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | Intellia Therapeutics, Inc. | REGA, KYLE THOMAS | 1636 | Non-Final OA | Jun 09, 2023 |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | Intellia Therapeutics, Inc. | KIM, TAEYOON | 1631 | Non-Final OA | Jun 09, 2023 |
| 18256516 | Biomarkers for Detecting Cancer | UNIVERSITY OF CAPE TOWN | COOK, LISA V | 1642 | Non-Final OA | Jun 08, 2023 |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | Cancer Research Technology Limited | HASTINGS, ALISON AZAR | 1627 | Non-Final OA | Jun 02, 2023 |
| 18323488 | Methods and Treatment for Complex Lymphatic Malformations | Avalo, Inc. | KOSTURKO, GEORGE W | 1621 | Non-Final OA | May 25, 2023 |
| 18254585 | Method for Reprogramming Cell | Celpaten Consulting Partnership (Limited Partnership) | BEHARRY, ZANNA MARIA | 1632 | Non-Final OA | May 25, 2023 |
| 18253485 | Method for Treating Antibody-Mediated Rejection | Csl Behring GmbH | FISHER, MELISSA L | 1658 | Non-Final OA | May 18, 2023 |
| 18035631 | Compositions and Methods for Treatment of DM1 with SLUCAS9 and SACAS9 | Vertex Pharmaceuticals Incorporated | HUDSON, AMY ROSE | 1636 | Non-Final OA | May 05, 2023 |
| 18035247 | METHOD FOR SANITIZING WASTE | Renescience A/S | CHOWDHURY, IQBAL HOSSAIN | 1656 | Non-Final OA | May 03, 2023 |
| 18035246 | METHOD FOR ENZYMATIC AND/OR MICROBIAL PROCESSING OF WASTE COMPRISING RECIRCULATION OF PROCESS WATER | Renescience A/S | ZINGARELLI, SANDRA | 1653 | Non-Final OA | May 03, 2023 |
| 18251523 | Combination Treatment of Cancer | Glaxosmithkline Intellectual Property (No. 4) Ltd. | XIAO, YAN | 1642 | Non-Final OA | May 02, 2023 |
| 18309388 | Combination Therapy | Seagen Inc. | XIAO, YAN | 1642 | Non-Final OA | Apr 28, 2023 |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | The Scripps Research Institute | FLINDERS, JEREMY C | 1684 | Non-Final OA | Apr 21, 2023 |
| 18033254 | Method and System of Sample Pooling and Processing | Unknown | HUANG, DAVID Z | 2855 | Non-Final OA | Apr 21, 2023 |
| 18032918 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | Athira Pharma, Inc. | JAVANMARD, SAHAR | 1622 | Non-Final OA | Apr 20, 2023 |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | Cancer Research Technology Limited | HSU, GRACE CHING | 1627 | Non-Final OA | Apr 18, 2023 |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | Woolsey Pharmaceuticals, Inc. | BAUER, NICOLA MARIA | 1621 | Non-Final OA | Apr 14, 2023 |
| 18132278 | Polynucleotides, Compositions, and Methods for Genome Editing | Intellia Therapeutics, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Final Rejection | Apr 07, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | Sorrento Therapeutics, Inc. | GAMETT, DANIEL C | 1647 | Non-Final OA | Apr 06, 2023 |
| 18189478 | METHODS OF TREATING PROTEINOPATHY ASSOCIATED WANDERING | Woolsey Pharmaceuticals, Inc. | JAVANMARD, SAHAR | 1622 | Non-Final OA | Mar 24, 2023 |
| 18002613 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Inhibrx Biosciences, Inc. | PATTERSON, SARAH COOPER | 1675 | Non-Final OA | Dec 20, 2022 |
| 18002336 | ONCOLYTIC HERPES SIMPLEX VIRUSES (HSV) EXPRESSING IMMUNOMODULATORY FUSION PROTEINS | Vivasor, Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | Non-Final OA | Dec 19, 2022 |
| 18081136 | Products Derived from Amniotic Fluid and Methods of Use | StimLabs, LLC | VAN BUREN, LAUREN K | 1638 | Non-Final OA | Dec 14, 2022 |
| 18001514 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT VASCULAR DEMENTIA | Woolsey Pharmaceuticals, Inc. | SONG, JIANFENG | 1613 | Final Rejection | Dec 12, 2022 |
| 18070908 | Compositions Derived from Placenta and Methods of Producing the Same | StimLabs, LLC | JOHNSON, KARA D | 1632 | Non-Final OA | Nov 29, 2022 |
| 17999459 | Low Diacetyl Yeast | Carlsberg A/S | DUFFY, PATRICIA ANN | 1645 | Non-Final OA | Nov 21, 2022 |
| 17985558 | Monitoring Cancer Stem Cells | Stemline Therapeutics, Inc. | CANELLA, KAREN A | 1643 | Non-Final OA | Nov 11, 2022 |
| 17923208 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS WITH AND WITHOUT A T CELL INHIBITORY PROTEIN AND METHODS OF USE THEREOF | Alpine Immune Sciences, Inc. | BUNNER, BRIDGET E | 1647 | Non-Final OA | Nov 03, 2022 |
| 18050333 | Methods of in Vitro Cell Delivery | Intellia Therapeutics, Inc. | ZHU, JIANJIAN | 1631 | Non-Final OA | Oct 27, 2022 |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | Avm Biotechnology, LLC | HAVLIN, ROBERT H | 1626 | Non-Final OA | Oct 25, 2022 |
| 17761483 | Artificial Prosthesis and Method for Manufacturing Same | Seoul National University Hospital | SNOW, BRUCE EDWARD | 3774 | Non-Final OA | Oct 07, 2022 |
| 17911808 | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection | Vitaeris Inc. | BUNNER, BRIDGET E | 1647 | Non-Final OA | Sep 15, 2022 |
| 17801293 | Lymphocyte Population and Methods for Producing Same | Avm Biotechnology, LLC | CHICKS, ASHLI ARIANA | 1626 | Non-Final OA | Aug 22, 2022 |
| 17800785 | METHODS FOR REDUCING HTT EXPRESSION | Ionis Pharmaceuticals, Inc. | CHONG, KIMBERLY | 1636 | Non-Final OA | Aug 18, 2022 |
| 17817777 | Composition and Methods for Selective Degradation of Engineered Proteins | Celgene Corporation | BOWLES, DAVID PAUL | 1654 | Final Rejection | Aug 05, 2022 |
| 17791113 | Decellularized Nerve Graft and Method of Manufacturing the Same | L&C Bio Co., Ltd. | TINSLEY, BRENDAN THOMAS | 1634 | Non-Final OA | Jul 06, 2022 |
| 17836265 | Modified Guide RNAs for Gene Editing | Intellia Therapeutics, Inc. | ARIETI, RUTH SOPHIA | 1635 | Non-Final OA | Jun 09, 2022 |
| 17781862 | Medical Composition Comprising Adipose Tissue-Derived Extracellular Matrix And Method For Preparing Same | L&C Bio Co., Ltd. | ALAWADI, SARAH | 1619 | Final Rejection | Jun 02, 2022 |
| 17777402 | Processes for the Preparation of Alpha-Hydroxy Esters via Grignard Coupling and Thiolation Reactions | Kemin Industries, Inc. | CARR, DEBORAH D | 1691 | Non-Final OA | May 17, 2022 |
| 17702452 | ORAL PHARMACEUTICAL IMMEDIATE RELEASE COMPOSITION AND METHOD OF TREATMENT FOR WEIGHT LOSS | Aardvark Therapeutics Inc. | LEE, ANDREW P | 1691 | Final Rejection | Mar 23, 2022 |
| 17760658 | Product for Therapy and Methods | The University of Bristol | TINSLEY, BRENDAN THOMAS | 1634 | Final Rejection | Mar 15, 2022 |
| 17642800 | Micro-Radiobinding Assays for Ligand Screening | Ac Immune SA | GROSS, CHRISTOPHER M | 1684 | Final Rejection | Mar 14, 2022 |
| 17639654 | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients | Cedars-Sinai Medical Center | OUSPENSKI, ILIA I | 1644 | Final Rejection | Mar 02, 2022 |
| 17637128 | Cardiovascular Risk Event Prediction and Uses Thereof | Somalogic Operating Co., Inc. | GOUGH, TIFFANY MAUREEN | 1651 | Non-Final OA | Feb 22, 2022 |
| 17571894 | TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND VEGF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | HOPKINS, SAMANTHA LAKE | 1641 | Non-Final OA | Jan 10, 2022 |
| 17624043 | Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damage with a CD84 Inhibitor | Julius-Maximilians-Universitaet-Wuerzburg | HOWARD, ZACHARY C | 1674 | Final Rejection | Dec 30, 2021 |
| 17618076 | Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof | Csl Innovation Pty., Ltd. | BELYAVSKYI, MICHAIL A | 1644 | Final Rejection | Dec 10, 2021 |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | Avm Biotechnology, LLC | SANG, HONG | 1646 | Non-Final OA | Dec 06, 2021 |
| 17612074 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | King'S College London | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | Nov 17, 2021 |
| 17437477 | Culture Method for Head and Neck Organoids | Koninklijke Nederlandse Akademie Van Wetenschappen | DUTT, ADITI | 1675 | Final Rejection | Sep 09, 2021 |
| 17394033 | HUMANIZED ANTIBODY | Genentech, Inc. | BALLARD, KIMBERLY | 1675 | Non-Final OA | Aug 04, 2021 |
| 17056103 | Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases | The Queensland Institute of Medical Research | GILL, RACHEL B | 1671 | Non-Final OA | Jul 01, 2021 |
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Inhibrx Biosciences, Inc. | EDGINGTONGIORDANO, FRANCESCA | 1643 | Final Rejection | Jun 25, 2021 |
| 17292025 | USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE RENAL TRANSPLANTATION IN HLA-SENSITIZED PATIENTS | Cedars-Sinai Medical Center | SULLIVAN, DENNIS JOHN | 1642 | Final Rejection | May 07, 2021 |
| 17288524 | T-Cell Receptors and Uses Thereof | The Queensland Institute of Medical Research | LI, RUIXIANG | 1674 | Non-Final OA | Apr 24, 2021 |
| 17111769 | Modified Guide RNAs for Gene Editing | Intellia Therapeutics, Inc. | PENNINGTON, KATIE LEIGH | 1634 | Final Rejection | Dec 04, 2020 |
| 16845280 | GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF | Vertex Pharmaceuticals Incorporated | SHIN, DANA H | 1635 | Final Rejection | Apr 10, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial